Key Points• Fibrin aC389-402 binds a cleft in the b-sandwich domain of FXIII-A 2 * exposed only after cleavage of the activation peptide.• Binding of fibrin aC389-402 to FXIII-A 2 * regulates fibrin cross-linking and thus clot stabilization and fibrinolysis.Formation of a stable fibrin clot is dependent on interactions between factor XIII and fibrin. We have previously identified a key residue on the aC of fibrin(ogen) (Glu396) involved in binding activated factor XIII-A 2 (FXIII-A 2 *); however, the functional role of this interaction and binding site(s) on FXIII-A 2 * remains unknown. Here we (1) characterized the functional implications of this interaction; (2) identified by liquidchromatography-tandem mass spectrometry the interacting residues on FXIII-A 2 * following chemical cross-linking of fibrin(ogen) aC389-402 peptides to FXIII-A 2 *; and (3) carried out molecular modeling of the FXIII-A 2 */peptide complex to identify contact site (s) involved. Results demonstrated that inhibition of the FXIII-A 2 */aC interaction using aC389-402 peptide (Pep1) significantly decreased incorporation of biotinamidopentylamine and a2-antiplasmin to fibrin, and fibrin cross-linking, in contrast to Pep1-E396A and scrambled peptide controls. Pep1 did not inhibit transglutaminase-2 activity, and incorporation of biotinyl-TVQQEL to fibrin was only weakly inhibited. Molecular modeling predicted that Pep1 binds the activation peptide cleft (AP-cleft) within the b-sandwich domain of FXIII-A 2 * localizing aC cross-linking Q366 to the FXIII-A 2 * active site. Our findings demonstrate that binding of fibrin aC389-402 to the APcleft is fundamental to clot stabilization and presents this region of FXIII-A 2 * as a potential site involved in glutamine-donor substrate recognition. (Blood. 2013;121(11):2117-2126
A novel class of potent FXIII-A inhibitors containing a (±) cis-bisamido epoxide pharmacophore is described. The compounds display highly potent inhibition of FXIII-A (IC 50 = 5-500 nM) in an in vitro assay. In contrast to other types of previously described covalent transglutaminase inhibitors, the bis-amido epoxides exhibited no measurable reactivity with glutathione, therefore possibly rendering this class of compounds suitable for future in vivo investigations. Additionally, the compounds show selective inhibition for FXIII-A against the cysteine protease, cathepsin S although they proved to have similar potency with a closely related transglutaminase, TGII, to that observed for FXIII-A.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.